Healthcare — Institutional Ownership & Hedge Fund Activity
Track hedge fund buying and selling activity in Healthcare stocks based on SEC 13F filings for Q2 2026.
Most Bought Healthcare Stocks
| # | Stock | Company | Funds Buying | Net $ Change |
|---|
| 1 | LLY | Eli Lilly and Company | 69 | $-2.2B |
| 2 | ABBV | AbbVie Inc. | 61 | +$871.6M |
| 3 | MRK | Merck & Co., Inc. | 57 | +$7.9M |
| 4 | JNJ | Johnson & Johnson | 56 | +$65.1M |
| 5 | BMY | Bristol-Myers Squibb Company | 41 | $-67.7B |
| 6 | ABT | Abbott Laboratories | 40 | +$203.8B |
| 7 | SYK | Stryker Corporation | 40 | +$107.5M |
| 8 | PFE | Pfizer Inc. | 37 | $-36.7B |
| 9 | MDT | Medtronic plc | 33 | +$13.9B |
| 10 | UNH | UnitedHealth Group Incorporated | 33 | +$684.3M |
| 11 | AMGN | Amgen Inc. | 31 | $-41.9M |
| 12 | GILD | Gilead Sciences, Inc. | 26 | +$363.4M |
| 13 | TMO | Thermo Fisher Scientific Inc. | 25 | $-21.0M |
| 14 | CVS | CVS Health Corp. | 23 | $-255.0B |
| 15 | DHR | Danaher Corporation | 23 | $-5.5B |
| 16 | ISRG | Intuitive Surgical, Inc. | 23 | $-46.1M |
| 17 | MCK | McKesson Corporation | 23 | $-238.3M |
| 18 | CI | Cigna Corporation | 20 | +$22.3M |
| 19 | NVO | Novo Nordisk A/S | 19 | +$6.0B |
| 20 | BDX | Becton, Dickinson and Company | 18 | +$24.8M |
Most Sold Healthcare Stocks
| # | Stock | Company | Funds Selling | Net $ Change |
|---|
| 1 | JNJ | Johnson & Johnson | 92 | +$65.1M |
| 2 | MRK | Merck & Co., Inc. | 73 | +$7.9M |
| 3 | ABBV | AbbVie Inc. | 70 | +$871.6M |
| 4 | AMGN | Amgen Inc. | 59 | $-41.9M |
| 5 | PFE | Pfizer Inc. | 59 | $-36.7B |
| 6 | LLY | Eli Lilly and Company | 53 | $-2.2B |
| 7 | UNH | UnitedHealth Group Incorporated | 53 | +$684.3M |
| 8 | ABT | Abbott Laboratories | 51 | +$203.8B |
| 9 | TMO | Thermo Fisher Scientific Inc. | 51 | $-21.0M |
| 10 | DHR | Danaher Corporation | 40 | $-5.5B |
| 11 | MDT | Medtronic plc | 39 | +$13.9B |
| 12 | BMY | Bristol-Myers Squibb Company | 35 | $-67.7B |
| 13 | ISRG | Intuitive Surgical, Inc. | 35 | $-46.1M |
| 14 | GILD | Gilead Sciences, Inc. | 32 | +$363.4M |
| 15 | CVS | CVS Health Corp. | 30 | $-255.0B |
| 16 | SYK | Stryker Corporation | 30 | +$107.5M |
| 17 | ZTS | Zoetis Inc. | 29 | +$44.0B |
| 18 | EW | Edwards Lifesciences Corporation | 25 | $-3.7B |
| 19 | MCK | McKesson Corporation | 23 | $-238.3M |
| 20 | BDX | Becton, Dickinson and Company | 22 | +$24.8M |
Most Widely Held Healthcare Stocks
| # | Stock | Company | Institutional Holders | Total Value |
|---|
| 1 | JNJ | Johnson & Johnson | 274 | $7.5B |
| 2 | LLY | Eli Lilly and Company | 248 | $7.0B |
| 3 | ABBV | AbbVie Inc. | 240 | $4.3B |
| 4 | MRK | Merck & Co., Inc. | 230 | $11.1B |
| 5 | UNH | UnitedHealth Group Incorporated | 176 | $3.1B |
| 6 | AMGN | Amgen Inc. | 176 | $1.7B |
| 7 | PFE | Pfizer Inc. | 175 | $1.1T |
| 8 | ABT | Abbott Laboratories | 173 | $1.7T |
| 9 | TMO | Thermo Fisher Scientific Inc. | 145 | $2.5B |
| 10 | BMY | Bristol-Myers Squibb Company | 144 | $1.1T |
| 11 | SYK | Stryker Corporation | 139 | $1.4B |
| 12 | MDT | Medtronic plc | 133 | $1.1T |
| 13 | CVS | CVS Health Corp. | 117 | $6.0B |
| 14 | GILD | Gilead Sciences, Inc. | 115 | $5.9B |
| 15 | ISRG | Intuitive Surgical, Inc. | 109 | $1.8B |
| 16 | DHR | Danaher Corporation | 107 | $3.9B |
| 17 | MCK | McKesson Corporation | 103 | $645.1M |
| 18 | CI | Cigna Corporation | 84 | $500.1M |
| 19 | VRTX | Vertex Pharmaceuticals Incorporated | 83 | $741.5M |
| 20 | AZN | AstraZeneca PLC | 82 | $4.3B |
Data sourced from SEC 13F filings for Q2 2026. Filings are delayed up to 45 days after quarter end.